デフォルト表紙
市場調査レポート
商品コード
1732822

人工多能性幹細胞生産市場- 世界の産業規模、シェア、動向、機会、予測、プロセス別、製品別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Process, By Product, By Application, By End-user, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
人工多能性幹細胞生産市場- 世界の産業規模、シェア、動向、機会、予測、プロセス別、製品別、用途別、エンドユーザー別、地域別、競合別、2020-2030年
出版日: 2025年05月23日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

人工多能性幹細胞（iPSC）製造の世界市場は、2024年に13億5,000万米ドルと評価され、予測期間中に10.44％のCAGRで成長し、2030年には24億5,000万米ドルに達すると予測されています。

iPSCは、自己複製と複数の細胞タイプへの分化能力により、再生医療における変革的イノベーションとして浮上しています。皮膚や血液のような成体細胞を再プログラムすることで得られるiPS細胞は、胚性幹細胞に似た性質を示す一方で、従来の供給源に関連する倫理的・免疫学的懸念に対処しています。その万能性から、再生治療、薬剤スクリーニング、疾患モデリングに不可欠なツールとして位置づけられています。iPSC技術の進歩に伴い、神経学、心臓病学、代謝性疾患などの分野での応用が拡大し、市場は急速に拡大しています。個別化医療へのシフトと成体由来細胞を使用することの倫理的利点が需要をさらに後押しし、iPSCは次世代生物医学研究と治療開発の要としての地位を確立しています。

市場概要
予測期間 2026-2030
市場規模：2024年 13億5,000万米ドル
市場規模：2030年 24億5,000万米ドル
CAGR：2025年～2030年 10.44%
急成長セグメント 医薬品開発・発見
最大市場 北米

市場促進要因

治療用途の拡大

主な市場課題

生産コスト

主な市場動向

疾患モデリングと医薬品開発における用途の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の人工多能性幹細胞生産市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • プロセス別（手動iPSC製造プロセス、自動iPSC製造プロセス）
    • 製品別（機器/デバイス、自動化プラットフォーム、消耗品とキット、サービス）
    • 用途別（医薬品開発・発見、再生医療、毒性学研究、その他）
    • エンドユーザー別（調査・学術機関、バイオテクノロジー・製薬会社、病院・クリニック）
    • 企業別（2024）
    • 地域別
  • 市場マップ

第6章 北米の人工多能性幹細胞生産市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の人工多能性幹細胞生産市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の人工多能性幹細胞生産市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の人工多能性幹細胞生産市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの人工多能性幹細胞生産市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Lonza Group
  • Axol Biosciences Ltd.
  • Evotec SE
  • Hitachi Ltd.
  • Reprocells Inc.
  • Fate Therapeutics.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Stemcellsfactory III
  • Applied Stemcells Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 16284

The Global Induced Pluripotent Stem Cells (iPSCs) Production Market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.45 billion by 2030, growing at a CAGR of 10.44% during the forecast period. iPSCs have emerged as a transformative innovation in regenerative medicine due to their ability to self-renew and differentiate into multiple cell types. Derived by reprogramming adult cells like those from skin or blood, iPSCs exhibit properties similar to embryonic stem cells while addressing ethical and immunological concerns associated with traditional sources. Their versatility positions them as vital tools for regenerative therapies, drug screening, and disease modeling. With advancements in iPSC technology, the market is expanding rapidly, driven by growing applications across neurology, cardiology, and metabolic disorders. The shift towards personalized medicine and the ethical benefits of using adult-derived cells further bolster demand, establishing iPSCs as a cornerstone in next-generation biomedical research and therapeutic development.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.35 Billion
Market Size 2030USD 2.45 Billion
CAGR 2025-203010.44%
Fastest Growing SegmentDrug Development and Discovery
Largest MarketNorth America

Key Market Drivers

Expanding Therapeutic Applications

The potential of iPSCs in clinical therapy is continuously growing as they are applied to an expanding spectrum of diseases. Their ability to differentiate into various specialized cell types makes them highly promising for treating complex conditions such as Parkinson's disease, Alzheimer's, cardiovascular disorders, and diabetes. iPSCs derived from adult cells can be engineered into dopaminergic neurons, offering targeted treatment pathways and facilitating drug development for neurodegenerative conditions. Similarly, their application in cardiac regeneration is gaining traction, with researchers using iPSC-derived cardiac cells to model heart diseases and explore regenerative options post-injury. The increasing adoption of iPSCs in these therapeutic areas not only enhances treatment potential but also broadens the market for their production, as healthcare systems and patients alike seek advanced, tailored solutions.

Key Market Challenges

Cost of Production

A major limitation hindering the widespread adoption of iPSC technologies is the high cost associated with their generation and maintenance. The reprogramming of adult cells into iPSCs involves resource-intensive processes that require high-end laboratory infrastructure, advanced equipment, and skilled personnel. Furthermore, the culture media and reagents used in iPSC production are costly and must comply with strict quality standards to ensure consistency and safety. These operational expenses create significant financial barriers for both academic and commercial entities attempting to scale production for therapeutic use. Consequently, the cost of iPSC-based therapies remains high, limiting accessibility for broader patient groups and posing challenges for market scalability.

Key Market Trends

Growing Applications in Disease Modeling and Drug Development

The increasing use of iPSCs in disease modeling and pharmaceutical research is a key trend driving market growth. iPSCs can be generated from individuals with specific genetic profiles, enabling the creation of personalized disease models. These models provide valuable platforms for understanding disease mechanisms and testing drug responses in conditions such as genetic disorders, neurodegenerative diseases, and cardiovascular anomalies. Pharmaceutical companies are leveraging iPSC technology to enhance drug discovery pipelines, enabling more accurate candidate screening and reducing development timelines and costs. The rising emphasis on precision medicine further amplifies the need for iPSC-derived models, reinforcing their significance in both academic research and commercial drug development.

Key Market Players

  • Lonza Group
  • Axol Biosciences Ltd.
  • Evotec SE
  • Hitachi Ltd.
  • Reprocells Inc.
  • Fate Therapeutics.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Stemcellsfactory III
  • Applied Stemcells Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Production Market, By Process:

  • Manual iPSC Production Process
  • Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market, By Product:

  • Instruments/ Devices
  • Automated Platforms
  • Consumables & Kits
  • Services

Induced Pluripotent Stem Cells Production Market, By End-user:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

Induced Pluripotent Stem Cells Production Market, By Application:

  • Drug Development and Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

Induced Pluripotent Stem Cells Production Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.

Available Customizations:

Global Induced Pluripotent Stem Cells Production market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Production Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Process (Manual iPSC Production Process, Automated iPSC Production Process)
    • 5.2.2. By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services)
    • 5.2.3. By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others)
    • 5.2.4. By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Production Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Process
    • 6.2.2. By Product
    • 6.2.3. By End-user
    • 6.2.4. By Application
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Process
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By End-user
        • 6.3.1.2.4. By Application
    • 6.3.2. Mexico Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Process
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By End-user
        • 6.3.2.2.4. By Application
    • 6.3.3. Canada Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Process
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By End-user
        • 6.3.3.2.4. By Application

7. Europe Induced Pluripotent Stem Cells Production Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Process
    • 7.2.2. By Product
    • 7.2.3. By End-user
    • 7.2.4. By Application
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Process
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By End-user
        • 7.3.1.2.4. By Application
    • 7.3.2. Germany Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Process
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By End-user
        • 7.3.2.2.4. By Application
    • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Process
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By End-user
        • 7.3.3.2.4. By Application
    • 7.3.4. Italy Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Process
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By End-user
        • 7.3.4.2.4. By Application
    • 7.3.5. Spain Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Process
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By End-user
        • 7.3.5.2.4. By Application

8. Asia-Pacific Induced Pluripotent Stem Cells Production Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Process
    • 8.2.2. By Product
    • 8.2.3. By End-user
    • 8.2.4. By Application
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Process
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By End-user
        • 8.3.1.2.4. By Application
    • 8.3.2. India Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Process
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By End-user
        • 8.3.2.2.4. By Application
    • 8.3.3. South Korea Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Process
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By End-user
        • 8.3.3.2.4. By Application
    • 8.3.4. Japan Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Process
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By End-user
        • 8.3.4.2.4. By Application
    • 8.3.5. Australia Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Process
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By End-user
        • 8.3.5.2.4. By Application

9. South America Induced Pluripotent Stem Cells Production Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Process
    • 9.2.2. By Product
    • 9.2.3. By End-user
    • 9.2.4. By Application
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Process
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By End-user
        • 9.3.1.2.4. By Application
    • 9.3.2. Argentina Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Process
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By End-user
        • 9.3.2.2.4. By Application
    • 9.3.3. Colombia Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Process
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By End-user
        • 9.3.3.2.4. By Application

10. Middle East and Africa Induced Pluripotent Stem Cells Production Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Process
    • 10.2.2. By Product
    • 10.2.3. By End-user
    • 10.2.4. By Application
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Process
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By End-user
        • 10.3.1.2.4. By Application
    • 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Process
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By End-user
        • 10.3.2.2.4. By Application
    • 10.3.3. UAE Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Process
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By End-user
        • 10.3.3.2.4. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Lonza Group
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Axol Biosciences Ltd.
  • 15.3. Evotec SE
  • 15.4. Hitachi Ltd.
  • 15.5. Reprocells Inc.
  • 15.6. Fate Therapeutics.
  • 15.7. Thermo Fisher Scientific, Inc.
  • 15.8. Merck KgaA
  • 15.9. Stemcellsfactory III
  • 15.10. Applied Stemcells Inc.

16. Strategic Recommendations

17. About Us & Disclaimer